Prometic Plans to Move Quickly With Rare Disease Candidate

Prometic Life Sciences CEO Pierre Laurin.

This morning, Prometic Life Sciences (TSX:PLI) announced that the FDA has cleared the company’s IV plasminogen to enter human testing for the treatment of hypoplasminogenemia. With its Investigational New Drug (IND) application approved, Prometic isn’t wasting anytime, it plans to commence a 6 patient Phase I study this quarter. That study will lead into a […]

Cipher Pharmaceuticals has multiple ways to create shareholder value, says Donville

"My guess is we are going to get reconciliation on this, one way or the other, in the next six months," says Jason Donville of Cipher Pharmaceuticals. "They're either going to buy a bunch of stuff and get a big pop in their rating, or they're going to get taken out by somebody".

Investors looking at Cipher Pharmaceuticals (TSX:DND) should know there is more than one way the company could deliver value for shareholders, says one portfolio manager. Jason Donville, President & CEO of Donville Kent Asset Management was on BNN’s “Market Call” Friday and revealed his current top picks. The portfolio manager says Cipher Pharma is valuable […]

TSO3 Awaits FDA Verdict After Label Submission

This morning, Quebec City based TSO3 (TSX: TOS) updated the markets on the status of their FDA 510(k) filing for their low temperature hospital sterilizer, Sterizone VP4. In a press release, the company stated that it has submitted revised labeling to FDA for both the sterilizer and accessory devices. In August of this year, the […]

Tekmira rises as production of Ebola treatment begins


Shares of Burnaby-based Tekmira (TSX:TKM, NASDAQ:TKMR) are up today after the company late yesterday announced it has started limited GMP manufacture of a new therapeutic that specifically targets the Ebola-Guinea variant, the viral variant responsible for the Ebola epidemic in West Africa. The company says the product should be available by December. In August, the […]

Valeant Q3 could prove it doesn’t need Allergan, says Paradigm


A strong third quarter from Valeant Pharmaceuticals (TSX:VRX) on October 20th could prove to the street that the company’s legacy business is strong and sustainable, says Paradigm Capital analyst Alan Ridgeway. In a research update to clients this morning, Ridgeway maintained his “Buy” rating and $160.00 target on Valeant, implying a return of 39% at […]

Opsens has huge upside, says Paradigm Capital

Opsens CEO Louis Laflamme.

The risk-to-reward ratio on Opsens (TSXV:OPS) is compelling, says Paradigm Capital analyst Alan Ridgeway. In a research update to clients yesterday, Ridgeway maintained his “Buy” rating and one-year target of $2.75 on Opsens, implying a return of 299% at the time of publication. The analyst’s update follows on the heels of Tuesday’s news in which […]

Shares of Tekmira soar after first U.S. Ebola case confirmed


Shares of Tekmira (TSX:TKM, Nasdaq:TKMR) are soaring in after market trading after news broke of the first diagnosis of Ebola in the United States. A patient at Dallas’s Texas Health Presbyterian Hospital has tested positive for Ebola, and is currently being treated. The Centers for Disease Control and Prevention this afternoon confirmed that the infected […]